🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5 results for “remifentanil” Clear

  1. Remifentanil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Analgesia

    phase 3 small molecule active

    1 trial

  2. Remifentanil

    Hospital Authority, Hong Kong

    Labor Pain

    approved small molecule active

    1 trial

  3. Esketamine, Sulfentanil or/and Remifentanil

    Second Affiliated Hospital of Soochow University

    Opioid Analgesic Adverse Reaction

    small molecule active

    1 trial

  4. Remifentanil

    Vera Therapeutics

    Postoperative Pain

    small molecule completed

    1 trial

  5. remimazolam combined with remifentanil

    The First People's Hospital of Lianyungang

    Difficult or Failed Intubation

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources